Genelux Corporation (GNLX) vs Lucid Diagnostics Inc. (LUCD)
A side-by-side comparison of Genelux Corporation and Lucid Diagnostics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GNLX
Genelux Corporation
$2.57HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
LUCD
Lucid Diagnostics Inc.
$0.61HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — GNLX vs LUCD
growth of $100 · dividends reinvested · last 4yGNLX -57.7% (-19.4%/yr)LUCD -51.4% (-16.5%/yr)LUCD compounded faster over this window
GNLX LUCD
GNLX vs LUCD: by the numbers
- •LUCD is the larger company ($116M vs $115M market cap).
- •Both run net losses; LUCD's is the smaller (-959.76% vs -422412.50% net margin).
Metrics side by side
Valuation
| Metric | GNLX | LUCD |
|---|---|---|
| P/S ratio | 14404.98 | 21.22 |
| P/B ratio | 7.15 | 10.58 |
Profitability
| Metric | GNLX | LUCD |
|---|---|---|
| Gross margin | -7075.00% | -60.26% |
| Operating margin | -415175.00% | -1054.82% |
| Net margin | -422412.50% | -959.76% |
| ROE | -209.73% | -478.26% |
| ROIC | -192.18% | -145.10% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.